Vanessa F Bonazzi
Overview
Explore the profile of Vanessa F Bonazzi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
575
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brosda S, Aoude L, Bonazzi V, Patel K, Lonie J, Belle C, et al.
Genome Med
. 2024 Jul;
16(1):90.
PMID: 39020404
Background: Oesophageal adenocarcinoma (OAC) is a highly heterogeneous cancer with poor survival. Standard curative treatment is chemotherapy with or without radiotherapy followed by oesophagectomy. Genomic heterogeneity is a feature of...
2.
Lonie J, Brosda S, Bonazzi V, Aoude L, Patel K, Brown I, et al.
Front Immunol
. 2023 Nov;
14:1220129.
PMID: 37965317
A plateau in treatment effect can be seen for the current 'one-size-fits-all' approach to oesophageal adenocarcinoma (OAC) management using neoadjuvant chemoradiotherapy (nCRT) or chemotherapy (nCT). In OAC, the tumour microenvironment...
3.
Aoude L, Brosda S, Ng J, Lonie J, Belle C, Patel K, et al.
J Mol Diagn
. 2023 Aug;
25(10):771-781.
PMID: 37544359
For patients with BRAF wild-type stage III and IV melanoma, there is an urgent clinical need to identify prognostic biomarkers and biomarkers predictive of treatment response. Circulating tumor DNA (ctDNA)...
4.
Bonazzi V, Aoude L, Brosda S, Bradford J, Lonie J, Loffler K, et al.
Asia Pac J Clin Oncol
. 2023 Jul;
21(1):77-86.
PMID: 37415393
Aim: The 5-year survival rate of pancreatic ductal adenocarcinoma (PDAC) is approximately 11% and has only improved marginally over the last three decades. For operable PDAC, resection and adjuvant FOLFIRINOX...
5.
Naeini M, Newell F, Aoude L, Bonazzi V, Patel K, Lampe G, et al.
Nat Commun
. 2023 May;
14(1):3155.
PMID: 37258531
Oesophageal adenocarcinoma is a poor prognosis cancer and the molecular features underpinning response to treatment remain unclear. We investigate whole genome, transcriptomic and methylation data from 115 oesophageal adenocarcinoma patients...
6.
Bonazzi V, Kondrashova O, Smith D, Nones K, Sengal A, Ju R, et al.
Genome Med
. 2022 Jan;
14(1):3.
PMID: 35012638
Background: Endometrial cancer (EC) is a major gynecological cancer with increasing incidence. It comprises four molecular subtypes with differing etiology, prognoses, and responses to chemotherapy. In the future, clinical trials...
7.
Wang J, Wuethrich A, Lobb R, Antaw F, Sina A, Lane R, et al.
ACS Sens
. 2021 Jul;
6(9):3182-3194.
PMID: 34264628
Identifying small extracellular vesicle (sEV) subpopulations based on their different molecular signatures could potentially reveal the functional roles in physiology and pathology. However, it is a challenge to achieve this...
8.
Aoude L, Wong B, Bonazzi V, Brosda S, Walters S, Koufariotis L, et al.
Mol Cancer Res
. 2021 Apr;
19(6):950-956.
PMID: 33811161
Treatment for metastatic melanoma includes targeted and/or immunotherapy. Although many patients respond, only a subset has complete response. As late-stage patients often have multiple tumors in difficult access sites, non-invasive...
9.
Aoude L, Bonazzi V, Brosda S, Patel K, Koufariotis L, Oey H, et al.
Sci Rep
. 2020 Oct;
10(1):17687.
PMID: 33077847
Patients with late stage resected cutaneous melanoma have poor overall survival (OS) and experience irreversible adverse events from systemic therapy. There is a clinical need to identify biomarkers to predict...
10.
Newell F, Patel K, Gartside M, Krause L, Brosda S, Aoude L, et al.
BMC Med Genomics
. 2019 Feb;
12(1):31.
PMID: 30717762
Background: Oesophageal adenocarcinoma (EAC) incidence is increasing and has a poor survival rate. Barrett's oesophagus (BE) is a precursor condition that is associated with EAC and often occurs in conjunction...